A 44-year-old man with a HIV infection and levels of CD4 < 100/mm3, under antiretroviral therapy and with a previous medical history of visceral leishmaniasis (VL), was admitted to hospital with progressive muscular weakness and paraesthesia in both legs for three months. Imaging procedures were performed, showing a leptomeningeal thickening and enlargement of hilar and mediastinal lymph nodes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ritonavir enhances the efficacy of amprenavir: a promising combination therapy by targeting Leishmania DNA Topoisomerase I for treatment of visceral leishmaniasis HIV-VL co-infection.
Exp Parasitol
January 2025
Department of Biotechnology, Savitribai Phule Pune University, Pune-411007, India. Electronic address:
Visceral leishmaniasis (VL) is an opportunistic infection in HIV patients with higher relapse and mortality rate. The number of HIV-VL patients is comparatively higher in areas where both infections are endemic. However, the conventional chemotherapeutic agents have limited success due to drug toxicity, efficacy variance and overall cost of treatment.
View Article and Find Full Text PDFSerosurvey of Visceral Leishmaniasis in Organ Transplant Recipients in the South of Iran.
Transplant Proc
January 2025
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:
Background: Visceral leishmaniasis (VL) can become active and cause specific problems in transplant recipients. The current study was conducted with the aim of serological evaluation of VL in transplant patients in a comprehensive transplantation center in Fars province southern Iran.
Methods: The study population included 150 organ transplant recipients.
Performance of Culture Using a Semi-Automatic Needle as a Novel Tool for Collecting Lymph Node Samples for the Diagnosis of Canine Visceral Leishmaniasis.
Animals (Basel)
January 2025
Laboratory of Clinical Research on Dermatozoonoses in Domestic Animals, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Av. Brasil, 4365, Rio de Janeiro 21040-360, Brazil.
Zoonotic visceral leishmaniasis is caused by () and dogs are the main domestic reservoir. This study compared the performance of parasitological tests using semi-automatic needle puncture (SANP) for collecting popliteal lymph node samples with samples collected from the same lymph node by fine needle aspiration puncture (FNAP) and by necropsy for the diagnosis of canine visceral leishmaniasis (CVL). Popliteal lymph node samples were collected from 30 CVL-seropositive dogs from an endemic region in Brazil.
View Article and Find Full Text PDFHuman migrations, anthropogenic changes, and insect-borne diseases in Latin America.
Parasit Vectors
January 2025
Department of Agriculture, Food and Environment, University of Pisa, Pisa, Italy.
Rapid urbanization and migration in Latin America have intensified exposure to insect-borne diseases. Malaria, Chagas disease, yellow fever, and leishmaniasis have historically afflicted the region, while dengue, chikungunya, and Zika have been described and expanded more recently. The increased presence of synanthropic vector species and spread into previously unaffected areas due to urbanization and climate warming have intensified pathogen transmission risks.
View Article and Find Full Text PDFClinical, histopathological and parasitological follow-up of dogs naturally infected by Leishmania infantum before and after miltefosine treatment and associated therapies.
PLoS One
January 2025
Department of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
In Brazil, Visceral Leishmaniases is caused by Leishmania infantum, and domestic dogs are the main reservoirs in its urban transmission cycle. As an alternative to euthanizing dogs, miltefosine has been used to treat canine visceral leishmaniasis since 2016. In this study, we have assessed the efficacy of miltefosine for treating canine visceral leishmaniasis in a new endemic area through follow-up of naturally infected dogs was evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!